Menu
← Oncology Approval Tracker
FDA DECISION ·
Calquence tablets
acalabrutinib maleate · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
The tablet formulation for adults with CLL or SLL, or mantle cell lymphoma after at least one prior therapy, as specified on its original label.
LAMPGEN ANALYSIS
Why it matters
The tablet gives a different oral presentation for existing acalabrutinib indications.
What research teams should watch
Document tablet versus capsule in medication reconciliation and check formulation-specific coadministration instructions.
PRIMARY RECORDS